Here's a recap of recent blog posts and other news.
The RxISK end-of-year message centres on the need for a new approach to healthcare.
Life expectancy in Western countries is falling. This fall does not stem from a new disorder that will respond to a new pharmaceutical or device. In fact it is quite the opposite. One contributory factor has to be the increasing number of medicines each of us takes every day (see the Welsh Senate Withdrawal Seminar blog post).
Taper MD -- our effort to turn things around -- is currently in clinical trials and in pilot roll-outs. It will launch in 2019.
Up to this point, the RxISK website has featured accounts of problems that arise
after a treatment begins and the difficulties in getting doctors to listen. We welcome any accounts readers have of how
de-prescribing has changed their lives or revealed problems from treatment they didn't know they were having, along with accounts of collaborative efforts with doctors to reduce their medication burden. If you are interested, and the accounts are suitable, these could run as blog posts on RxISK.
Thank you for your support.
Your feedback, as always, is greatly appreciated.
David Healy, MD
|
